Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 256 AL 270

The Rationale for Insulin Therapy in Alzheimer's Disease

Ribarič S.

Molecules. 2016 May 26;21(6):689. doi: 10.3390/molecules21060689.

Identifying and Managing Pain in People with Alzheimer's Disease and Other Types of Dementia: A Systematic Review

Husebo BS, Achterberg W, Flo E.

CNS Drugs. 2016 Jun;30(6):481-97. doi: 10.1007/s40263-016-0342-7.

Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease

Kulshreshtha A, Piplani P.

Neurol Sci. 2016 Sep;37(9):1403-35. doi: 10.1007/s10072-016-2625-7. Epub 2016 Jun 1.

Improving Memory and Cognition in Individuals with Down Syndrome

Rafii MS.

CNS Drugs. 2016 Jul;30(7):567-73. doi: 10.1007/s40263-016-0353-4.

Improving Prospective Memory in Healthy Older Adults and Individuals with Very Mild Alzheimer's Disease

Shelton JT, Lee JH, Scullin MK, Rose NS, Rendell PG, McDaniel MA.

J Am Geriatr Soc. 2016 Jun;64(6):1307-12. doi: 10.1111/jgs.14134.

Antihypertensiva-Stopp ohne Effekt auf die kognitive Funktion alter Menschen

Zechmann S.

Praxis (Bern 1994). 2016 Jul;105(15):917-8. doi: 10.1024/1661-8157/a002417.

Therapies for Prevention and Treatment of Alzheimer's Disease

Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G.

Biomed Res Int. 2016;2016:2589276. doi: 10.1155/2016/2589276. Epub 2016 Jul 28.

Drug use in persons with and without Alzheimer's disease aged 90 years or more

Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S.

Age Ageing. 2016 Nov;45(6):900-904. doi: 10.1093/ageing/afw141. Epub 2016 Sep 8.

Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease

Cavedo E, Dubois B, Colliot O, Lista S, Croisile B, Tisserand GL, Touchon J, Bonafe A, Ousset PJ, Rouaud O, Ricolfi F, Vighetto A, Pasquier F, Galluzzi S, Delmaire C, Ceccaldi M, Girard N, Lehericy S, Duveau F, Chupin M, Sarazin M, Dormont D, Hampel H; Hippocampus Study Group.

J Clin Psychiatry. 2016 Dec;77(12):e1631-e1638. doi: 10.4088/JCP.15m10413.

Technology-enhanced multi-domain at home continuum of care program with respect to usual care for people with cognitive impairment: the Ability-TelerehABILITation study protocol for a randomized controlled trial

Realdon O, Rossetto F, Nalin M, Baroni I, Cabinio M, Fioravanti R, Saibene FL, Alberoni M, Mantovani F, Romano M, Nemni R, Baglio F.

BMC Psychiatry. 2016 Nov 25;16(1):425. doi: 10.1186/s12888-016-1132-y.

The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease

Grizzanti J, Lee HG, Camins A, Pallas M, Casadesus G.

Nutr Res. 2016 Dec;36(12):1305-1315. doi: 10.1016/j.nutres.2016.11.002. Epub 2016 Nov 8.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

Delnomdedieu M, Duvvuri S, Li DJ, Atassi N, Lu M, Brashear HR, Liu E, Ness S, Kupiec JW.

Alzheimers Res Ther. 2016 Mar 1;8(1):12. doi: 10.1186/s13195-016-0177-y.

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L.

Alzheimers Res Ther. 2016 Apr 6;8(1):14. doi: 10.1186/s13195-016-0181-2.

[Development of Disease-modifying Therapy for Alzheimer's Disease]

Akiyama H.

Brain Nerve. 2016 Apr;68(4):463-72. doi: 10.11477/mf.1416200419.

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab

Russu A, Samtani MN, Xu S, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Liu E, Brashear HR, Styren S, Hu C.

J Alzheimers Dis. 2016 May 3;53(2):535-46. doi: 10.3233/JAD-151065.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias